Xention Participates in €12 Million Atrial Fibrillation Research Consortium
Consortium awarded five-year European Union grant under Seventh Framework programme
The consortium will undertake a five-year research project with the objective of improving the diagnosis, prevention and treatment of AF through the application of a highly integrative research approach.
‘Xention has a broad programme of research and development in atrial fibrillation and is delighted to participate in this consortium with a network of highly respected scientific institutions and clinical experts’ said Tim Brears CEO of Xention. Xention’s role in the consortium will be to characterize molecular biomarkers of abnormal function of ion channels known to play a role in atrial fibrillation, to validate newly identified ion channels that may have therapeutic potential in AF and to identify pharmacological tools to validate such channels.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.